Divi's Laboratories Limited

NSE DIVISLAB.NS

Divi's Laboratories Limited EBITDA for the year ending March 31, 2024: USD 304.88 M

Divi's Laboratories Limited EBITDA is USD 304.88 M for the year ending March 31, 2024, a -7.66% change year over year. EBITDA means earnings before interest, taxes, depreciation, and amortization, which measures a company's operating performance by excluding non-operating expenses.

Divi's Laboratories Limited EBITDA for the year ending March 31, 2023 was USD 330.18 M, a -37.28% change year over year.
Divi's Laboratories Limited EBITDA for the year ending March 31, 2022 was USD 526.40 M, a 31.83% change year over year.
Divi's Laboratories Limited EBITDA for the year ending March 31, 2021 was USD 399.29 M, a 49.49% change year over year.
Divi's Laboratories Limited EBITDA for the year ending March 31, 2020 was USD 267.10 M, a -8.42% change year over year.

Key data

Date	EBITDA	Net Income	EPS (Diluted)	Shares (Diluted, Weighted)

NSE: DIVISLAB.NS

Divi's Laboratories Limited

CEO	Dr. Kiran Satchandra Divi B. Pharm., M.Pharm
IPO Date	March 12, 2003
Location	India
Headquarters	Divi Towers
Employees	9,741
Sector	Health Care
Industries Pharmaceuticals Biotechnology

Description

Divi's Laboratories Limited manufactures and sells generic active pharmaceutical ingredients (APIs) and intermediates, and nutraceutical ingredients in India, the United States, Asia, Europe, and internationally. It also undertakes custom synthesis of APIs and intermediates; and supplies a range of carotenoids, as well as markets vitamins to nutritional, pharma, food/beverage, and feed industries. The company was formerly known as Divi's Research Center and changed its name to Divi's Laboratories Limited in 1994. The company was incorporated in 1990 and is headquartered in Hyderabad, India.

Key trends

Past 5 years